Form D · Biotechnology

Elysium Therapeutics, Inc.

Akron, OH · CIK 0001726100

Offering snapshot reported Oct 11, 2022 · SEC filing

Reported sold: $2.23M
Investors reported: 30
Minimum accepted: $0
First sale: Sep 27, 2022

Fundraising history

Reported sold

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

Reported sold$915,000 → $2,226,000
Reported investors23 → 30
Minimum accepted$1 → $0

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Oct 11, 2022	Amendment	$2,226,000	$1,311,000vs Nov 16, 2020	30	SEC filing
Nov 16, 2020	Initial	$915,000	No comparison	23	SEC filing
Mar 25, 2019	Initial	$214,992	No comparison	4	SEC filing
Sep 20, 2018	Initial	$931,985	No comparison	21	SEC filing
Dec 22, 2017	Initial	$651,778	No comparison	14	SEC filing

Offering details

Securities: Equity, Option to acquire, Security to be acquired
Exemptions: 06b
Duration over one year: No
Business combination: No

Sales commissions: $0
Finders' fees: $0
Form D file number: 021-380638

Source: Form D, filed Oct 11, 2022. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
James Hackworth	Director
Thomas Jenkins	Director
Kathy La Porte	Director
Carey Ng	Director
Bob Rappaport	Director
Alex Gregory Sturmer	Director, Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:

1201 East Market St., Suite 604
Akron, OH, 44305